文献速递膀胱癌与上尿路尿路上皮癌

三联治疗后挽救性膀胱切除术的并发症与结局

Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
PubMed 文献 · J Urol · 2021-02-22

该回顾性队列纳入265例2003至2013年在麻省总医院接受根治性膀胱切除术的cT1-T4膀胱癌患者,比较三联治疗后挽救性膀胱切除、原发膀胱切除及有非三联放化疗腹部盆腔放疗史的原发膀胱切除三组的术后结局。结果显示三组术中及早期并发症无差异,挽救性膀胱切除的晚期并发症及重大晚期并发症风险更高,但疾病特异性生存和总生存无差异。

要点

  • 挽救性膀胱切除的术中及早期并发症与原发膀胱切除相当。
  • 挽救性膀胱切除的晚期及重大晚期并发症风险显著高于原发膀胱切除。
  • 三组间疾病特异性生存和总生存无差异。

核心结论

  • 三联治疗后挽救性膀胱切除的术中及早期并发症发生率与原发膀胱切除及有非三联放疗史的原发膀胱切除相当。
  • 挽救性膀胱切除与更高的任何晚期并发症(HR 2.3,p=0.02)和重大晚期并发症(HR 2.1,p<0.05)风险相关。
  • 需要挽救性膀胱切除的患者疾病特异性生存(p=0.8)和总生存(p=0.9)与两组原发膀胱切除相当。

研究设计与样本

  • 回顾性队列研究,纳入265例2003至2013年在麻省总医院因cT1-T4膀胱癌接受根治性膀胱切除术的患者。
  • 按挽救性膀胱切除(三联治疗后)、原发膀胱切除、有非三联放化疗腹部盆腔放疗史的原发膀胱切除分组。
  • 比较早期(≤90天)和晚期(>90天)并发症,采用Cox回归模型计算生存并生成校正生存曲线。

主要发现

  • 中位随访自膀胱切除起为65.5个月。
  • 术中及早期并发症在三组间无差异。
  • 挽救性膀胱切除的晚期并发症检出率高于原发膀胱切除及有非三联放疗史的原发膀胱切除(p=0.03)。
  • 多因素Cox回归中,挽救性膀胱切除与任何晚期并发症(HR 2.3,p=0.02)和重大晚期并发症(HR 2.1,p<0.05)发生率更高相关。
  • 疾病特异性生存(p=0.8)和总生存(p=0.9)在三组间无差异。

临床怎么用

  • 对三联治疗后膀胱内复发需挽救性膀胱切除的患者,应预期晚期并发症风险较高并加强术后随访。
  • 挽救性膀胱切除的肿瘤学生存与原发膀胱切除相当,不应因既往三联治疗而排除手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Salvage cystectomy is required for some patients with intravesical recurrence after trimodality therapy. We compared postoperative outcomes between salvage cystectomy post-trimodality therapy, primary cystectomy and primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy. MATERIALS AND METHODS: We included 265 patients who underwent radical cystectomy at Massachusetts General Hospital for cT1-T4 bladder cancer between 2003 and 2013. Patients were grouped as salvage cystectomy post-trimodality therapy, primary cystectomy or primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy. Early (≤90 days) and late (>90 days) complications were compared. Disease-specific survival and overall survival were calculated using a Cox regression model, and adjusted survival curves were generated. RESULTS: The median followup from the time of cystectomy was 65.5 months. There was no difference in intraoperative and early complications between the groups. The detection of late complications was higher in salvage cystectomy post-trimodality therapy compared to primary cystectomy and primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy (p=0.03). In multivariable Cox regression analysis, salvage cystectomy post-trimodality therapy was associated with a higher incidence of any late (HR 2.3, p=0.02) and major late complications (HR 2.1, p <0.05). There was no difference in disease-specific survival (p=0.8) or overall survival (p=0.9) between the groups. CONCLUSIONS: Salvage cystectomy post-trimodality therapy for intravesical recurrence post-trimodality therapy has an intraoperative and early complication rate comparable to primary cystectomy and primary cystectomy with prior history of nontrimodality therapy abdominal or pelvic radiotherapy. Salvage cystectomy post-trimodality therapy is associated with a higher risk of overall and major late complications than primary cystectomy. The disease-specific survival and overall survival of patients who require salvage cystectomy post-trimodality therapy are comparable to both groups.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Pieretti A, Krasnow R, Drumm M, et al. Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. J Urol. 2021. PMID: 33617327. doi:10.1097/JU.0000000000001696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。